Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Atomi Financial Group Inc.

Atomi Financial Group Inc. raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 21.5% in the 1st quarter, Holdings Channel reports. The fund owned 882 shares of the pharmaceutical company’s stock after purchasing an additional 156 shares during the period. Atomi Financial Group Inc.’s holdings in Vertex Pharmaceuticals were worth $369,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. Venturi Wealth Management LLC grew its position in shares of Vertex Pharmaceuticals by 1.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock worth $933,000 after buying an additional 24 shares in the last quarter. Nicholas Hoffman & Company LLC. grew its position in shares of Vertex Pharmaceuticals by 3.9% during the fourth quarter. Nicholas Hoffman & Company LLC. now owns 636 shares of the pharmaceutical company’s stock worth $259,000 after buying an additional 24 shares in the last quarter. Hohimer Wealth Management LLC grew its position in shares of Vertex Pharmaceuticals by 0.8% during the fourth quarter. Hohimer Wealth Management LLC now owns 2,932 shares of the pharmaceutical company’s stock worth $1,193,000 after buying an additional 24 shares in the last quarter. Johnson Financial Group Inc. grew its position in shares of Vertex Pharmaceuticals by 2.5% during the fourth quarter. Johnson Financial Group Inc. now owns 1,001 shares of the pharmaceutical company’s stock worth $407,000 after buying an additional 24 shares in the last quarter. Finally, Arthur M. Cohen & Associates LLC grew its position in shares of Vertex Pharmaceuticals by 3.2% during the fourth quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock worth $326,000 after buying an additional 25 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on VRTX. Oppenheimer reissued an “outperform” rating and set a $500.00 price target on shares of Vertex Pharmaceuticals in a research report on Monday, April 15th. Evercore ISI upgraded Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price objective on the stock in a research note on Thursday, April 11th. StockNews.com upgraded Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 2nd. Canaccord Genuity Group restated a “sell” rating and set a $371.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday, April 12th. Finally, Wells Fargo & Company raised their price objective on Vertex Pharmaceuticals from $540.00 to $555.00 and gave the stock an “overweight” rating in a research note on Monday, June 24th. Three research analysts have rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $452.57.

Insider Buying and Selling

In related news, CMO Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $487.34, for a total transaction of $1,111,135.20. Following the transaction, the chief marketing officer now directly owns 27,819 shares of the company’s stock, valued at $13,557,311.46. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Vertex Pharmaceuticals news, EVP Edward Morrow Atkinson III sold 7,288 shares of the business’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $478.00, for a total transaction of $3,483,664.00. Following the sale, the executive vice president now owns 15,972 shares in the company, valued at approximately $7,634,616. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CMO Carmen Bozic sold 2,280 shares of the company’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $487.34, for a total value of $1,111,135.20. Following the completion of the transaction, the chief marketing officer now owns 27,819 shares in the company, valued at approximately $13,557,311.46. The disclosure for this sale can be found here. Insiders have sold a total of 30,646 shares of company stock valued at $14,169,923 over the last three months. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX traded up $4.70 during midday trading on Monday, reaching $493.44. 504,077 shares of the company traded hands, compared to its average volume of 1,210,280. Vertex Pharmaceuticals Incorporated has a 52 week low of $340.20 and a 52 week high of $496.71. The stock has a 50-day moving average price of $461.03 and a 200 day moving average price of $432.07. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.50 and a quick ratio of 3.29. The company has a market cap of $127.33 billion, a price-to-earnings ratio of 31.72, a PEG ratio of 2.52 and a beta of 0.39.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.66 by $1.10. The firm had revenue of $2.69 billion for the quarter, compared to analyst estimates of $2.58 billion. Vertex Pharmaceuticals had a return on equity of 23.08% and a net margin of 39.46%. Vertex Pharmaceuticals’s revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the company earned $2.67 earnings per share. Sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.16 earnings per share for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.